

AGE|RECODE®

CLINICAL PROTOCOL & INFO SHEET



GLP-1 BOOST™

**Natural GLP-1 Activation · Thermogenic Support
Peptide Metabolic Synergy**

MOTS-c Vitality Complex

GLP-1 BOOST™

Clinical Abstract

GLP-1 BOOST is an advanced MOTS-c Vitality Complex – a multi-ingredient metabolic peptide and botanical signaling stack formulated to support natural GLP-1 pathway activation, glucose metabolism, thermogenesis, and lean mass preservation. Designed as a practitioner-directed adjunct, it integrates MOTS-c and mclRBP-19 peptides with a comprehensive suite of metabolic botanicals and nutraceuticals, delivered via AgeREcode's patent-pending enteric-coated multi-phase oral capsule platform for optimized intestinal peptide absorption.

The formulation targets five key metabolic and signaling domains:

- 1. Natural GLP-1 Pathway Activation** – Berberine, EGCG, cinnamon, and ginger synergistically support endogenous incretin signaling cascades
- 2. Thermogenesis & Lipolysis** – EGCG (green tea), synephrine (bitter orange), and resveratrol activate fat oxidation and thermogenic pathways
- 3. Glucose Disposal & AMPK Activation** – Berberine, chromium picolinate, and resveratrol support insulin-mediated glucose uptake and AMPK signaling
- 4. Peptide Hormone Mimetics** – MOTS-c (mitochondrial-derived peptide, insulin sensitizer) and mclRBP-19 (insulin receptor-binding peptide mimetic)
- 5. Lean Mass Preservation** – HMB and resveratrol support anti-catabolic signaling and muscle protein anabolism during caloric deficit

Clinical Indications

- Adjunct to GLP-1 agonist prescriptions (semaglutide, tirzepatide, retatrutide)
- Natural GLP-1 pathway support for metabolic health programs
- Weight loss resistance or metabolic adaptation plateaus
- Body composition optimization with lean mass preservation priority
- Appetite dysregulation and satiety support protocols
- Blood glucose modulation and insulin sensitivity enhancement protocols

Suggested Use

- 1 capsule each morning on an empty stomach or with GLP-1 medication dosing
- Suggested cycle: 5 days on / 2 days off
- May be taken alongside GLP-1 agonist prescriptions as adjunct support
- Practitioner monitoring recommended; assess metabolic response at 4–6 weeks

Formulation (Per Capsule)

Active Ingredient	Amount	Primary Role
Berberine HCl	250 mg	AMPK activator; glucose disposal; GLP-1 pathway modulation
HMB (Ca Salt)	250 mg	Lean mass preservation; anti-catabolic; muscle protein synthesis
Green Tea Extract (50% EGCG)	125 mg	Thermogenesis; lipolysis; fat oxidation via EGCG/caffeine synergy
Bitter Orange Extract (6% syn.)	25 mg	Adrenergic thermogenic activation; lipolysis; metabolic rate support
Ginger Root Extract (5%)	50 mg	GI tolerability; GLP-1 pathway support; anti-inflammatory metabolic effects
Ceylon Cinnamon Extract	50 mg	Insulin sensitivity; glucose uptake; post-prandial glucose modulation
Resveratrol (trans-)	50 mg	AMPK/SIRT1 activation; lean mass support; mitochondrial biogenesis
Chromium Picolinate	200 mcg	Insulin cofactor; glucose metabolism support; chromium repletion
MOTS-c Peptide	500 mcg	Mitochondrial-derived peptide; insulin sensitization; AMPK activation
mclRBP-19 Peptide	500 mcg	Insulin receptor-binding mimetic; glucose regulation signaling

Other Ingredients: Vegan Capsule Shell, Magnesium Stearate, Silicon Dioxide, Mannitol.

Delivery: Size 00 HPMCAS enteric-coated capsule | Trehalose + Mannitol peptide stabilization matrix

Mechanistic Highlights

Pathway	Active Agents
GLP-1 Pathway Support	Berberine, Ginger, EGCG, Ceylon Cinnamon
Lipolysis / Fat Oxidation	EGCG, Synephrine, Resveratrol
Glucose Disposal / AMPK	Berberine, Chromium, Resveratrol
Lean Mass Preservation	HMB, Resveratrol (AMPK/SIRT1 axis)
Peptide Hormone Mimetics	MOTS-c (insulin sensitizer), mclRBP-19 (insulin mimetic)
GI Tolerability Support	Ginger Root Extract, peptide matrix stabilizers
Mitochondrial Activation	MOTS-c, Resveratrol, EGCG

Practitioner Applications

- **GLP-1 Adjunct Therapy** — Enhance and support GLP-1 agonist protocols; reduce metabolic plateau risk
- **Natural Metabolic Signaling** — Botanical GLP-1 pathway activation for non-pharmaceutical preference patients
- **Weight Management Programs** — Comprehensive thermogenic + appetite + lean mass stack
- **Insulin Sensitivity Protocols** — Multi-pathway glucose disposal and AMPK activation support
- **Body Composition Optimization** — Preserve lean muscle during caloric restriction via HMB/AMPK axis
- **Mitochondrial & Longevity Protocols** — MOTS-c peptide + resveratrol SIRT1 activation for healthspan support

Stacking Synergy

- With GLP PLUS+ – Complementary GLP-1 signaling; Orforglipron agonism + natural pathway activation
- With REcover™ – GI repair, mucosal protection, and post-weight loss GI recovery
- With REvive™ – Cellular energy amplification, NAD+, SIRT1, 1-MQ mitochondrial axis
- With REbalance™ – Hormonal optimization, cortisol regulation, adrenal and sleep support

Manufacturing & Quality

- HPMCAS enteric-coated capsule (Size 00) – protects botanicals and peptides through gastric transit
- HPLC purity ³99% for all actives including peptides | Trehalose + Mannitol peptide stabilization matrix
- cGMP manufacturing | 24-month validated stability | Third-party tested | Made in USA

Healthcare Professional Disclaimer: This document is intended for use by licensed healthcare professionals only. The information provided is for educational and informational purposes and is not intended to replace independent clinical judgment, diagnosis, or treatment decisions. GLP BOOST is provided for research and development use only. It is not a drug, medicine, supplement, or food. It is not intended to treat, diagnose, cure, or prevent any disease, ailment, or medical condition. These statements have not been evaluated by the Food and Drug Administration. Clinical application, patient selection, and dosing decisions are the sole responsibility of the treating healthcare provider. Published research and mechanistic data referenced herein relate to individual ingredients and biological pathways and do not constitute claims of clinical efficacy. Outcomes may vary based on patient factors, comorbidities, and concurrent therapies.